Compare Sun Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ALEMBIC PHARMA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ALEMBIC PHARMA SUN PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 21.1 15.3 137.9% View Chart
P/BV x 2.5 3.8 65.0% View Chart
Dividend Yield % 0.6 1.0 64.5%  

Financials

 SUN PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
ALEMBIC PHARMA
Mar-19
SUN PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs679664 102.2%   
Low Rs375412 91.0%   
Sales per share (Unadj.) Rs121.1208.7 58.0%  
Earnings per share (Unadj.) Rs13.431.0 43.2%  
Cash flow per share (Unadj.) Rs20.737.1 55.7%  
Dividends per share (Unadj.) Rs2.755.50 50.0%  
Dividend yield (eoy) %0.51.0 51.1%  
Book value per share (Unadj.) Rs172.6144.2 119.7%  
Shares outstanding (eoy) m2,399.26188.52 1,272.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.42.6 168.7%   
Avg P/E ratio x39.417.4 227.0%  
P/CF ratio (eoy) x25.514.5 175.7%  
Price / Book Value ratio x3.13.7 81.8%  
Dividend payout %20.617.7 115.9%   
Avg Mkt Cap Rs m1,264,650101,461 1,246.4%   
No. of employees `00017.5NA-   
Total wages/salary Rs m59,6717,467 799.1%   
Avg. sales/employee Rs Th16,608.1NM-  
Avg. wages/employee Rs Th3,409.6NM-  
Avg. net profit/employee Rs Th1,833.8NM-  
INCOME DATA
Net Sales Rs m290,65939,347 738.7%  
Other income Rs m10,25594 10,932.7%   
Total revenues Rs m300,91439,441 763.0%   
Gross profit Rs m63,0768,736 722.0%  
Depreciation Rs m17,5331,152 1,521.5%   
Interest Rs m5,553184 3,016.0%   
Profit before tax Rs m50,2467,493 670.6%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,0091,568 383.3%   
Profit after tax Rs m32,0935,844 549.2%  
Gross profit margin %21.722.2 97.7%  
Effective tax rate %12.020.9 57.2%   
Net profit margin %11.014.9 74.3%  
BALANCE SHEET DATA
Current assets Rs m310,69219,577 1,587.0%   
Current liabilities Rs m173,39614,896 1,164.0%   
Net working cap to sales %47.211.9 397.0%  
Current ratio x1.81.3 136.3%  
Inventory Days Days9990 110.4%  
Debtors Days Days11245 246.0%  
Net fixed assets Rs m232,47727,097 857.9%   
Share capital Rs m2,399377 636.4%   
"Free" reserves Rs m411,69126,811 1,535.5%   
Net worth Rs m414,09127,188 1,523.1%   
Long term debt Rs m15,2264,993 304.9%   
Total assets Rs m646,93847,778 1,354.1%  
Interest coverage x10.041.7 24.1%   
Debt to equity ratio x00.2 20.0%  
Sales to assets ratio x0.40.8 54.6%   
Return on assets %5.812.6 46.1%  
Return on equity %7.821.5 36.1%  
Return on capital %10.223.6 43.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02519,453 339.4%   
Fx outflow Rs m38,6106,065 636.6%   
Net fx Rs m27,41513,388 204.8%   
CASH FLOW
From Operations Rs m21,9658,120 270.5%  
From Investments Rs m-6,813-7,556 90.2%  
From Financial Activity Rs m-27,305590 -4,624.9%  
Net Cashflow Rs m-8,4421,153 -731.9%  

Share Holding

Indian Promoters % 63.7 74.1 86.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 2.9 176.9%  
FIIs % 23.0 9.1 252.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 13.9 59.7%  
Shareholders   133,026 49,328 269.7%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   UNICHEM LAB  VENUS REMEDIES  IPCA LABS  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare SUN PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Lower, India's October Exports, and Top Cues in Focus Today(Pre-Open)

India share markets ended their day marginally lower yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 72 points (down 0.2%).

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Nov 18, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - STERLING BIOTECH COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS